Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Monza – page 233

2 831 clinical trials in Monza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Monza at a glance
2 831
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 831 trials in Monza

Open in trial search

Colon cancer

Not recruiting

Comparison of drug combinations containing irinotecan, oxaliplatin, fluorouracil and folinic acid for treatment of high-risk stage III colon cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Unicancer

Bronchopulmonary dysplasia

Not recruiting

Study on Mecasermin Rinfabate for Preventing Chronic Lung Disease in Extremely Premature Babies

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Mecasermin Rinfabate
  • Sponsor:Ohb Neonatology Limited

Plasma cell myeloma

Not recruiting

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:European Myeloma Network B.V.

Intraductal proliferative breast lesion

Not recruiting

Evaluation of Contrast-Enhanced Spectral Mammography Using Iopromide in Women with Suspicious Breast Lesions to Improve Diagnostic Accuracy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iopromide
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Bladder cancer

Not recruiting

Study of Sacituzumab Govitecan for Patients with Muscle-Invasive Bladder Cancer Unable or Unwilling to Use Cisplatin-Based Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Ospedale San Raffaele S.r.l.

Neoplasm

Not recruiting

Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Metastatic malignant melanoma

Not recruiting

Study on Nemvaleukin Alfa and Pembrolizumab for Patients with Advanced Skin or Mucosal Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Endometrial cancer+2

Not recruiting

Study on Selinexor as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Selinexor
  • Sponsor:Karyopharm Therapeutics Inc.

Hepatocellular carcinoma

Not recruiting

Study on the Safety and Effects of Durvalumab, Tremelimumab, and Bevacizumab in Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Aveo Pharmaceuticals Inc.

Nasopharyngeal cancer

Not recruiting

Study of Pembrolizumab and Olaparib for Adults with Recurrent or Metastatic, Platinum-Resistant Nasopharyngeal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Fondazione GONO Plus

Glomerulonephritis membranous

Not recruiting

Study of Obinutuzumab for Patients with Primary Membranous Nephropathy Resistant or Intolerant to Rituximab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:Mario Negri Institute For Pharmacological Research

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Monza

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments and novel approaches for lymphoma management. Studies include targeted therapies and immunotherapy combinations.

  • NSCLC Treatment Studies
  • Lymphoma Therapy Innovations
  • Breast Cancer Research

Advanced investigations into personalized treatment approaches for various cancer types using targeted therapies and immunological interventions.

02 Autoimmune Conditions

Research focusing on psoriatic arthritis and multiple sclerosis, evaluating novel biological treatments and their effectiveness in managing disease progression.

  • Inflammatory Disease Studies
  • Biomarker Research
  • Treatment Response Evaluation

Comprehensive studies examining new therapeutic approaches for chronic autoimmune conditions.

03 Infectious Diseases

Vaccine development studies targeting Herpes Zoster and Cytomegalovirus, focusing on prevention and immune response in different age groups.

  • Vaccine Efficacy Studies
  • Long-term Immunity Research
  • Viral Prevention Strategies

Advanced clinical trials evaluating new vaccination approaches and therapeutic strategies.

04 Cardiovascular Studies

Innovative research on heart failure prevention and pulmonary arterial hypertension, testing new therapeutic combinations and treatment approaches.

  • Preventive Cardiology
  • Hypertension Management
  • Drug Combination Studies

Investigation of novel therapeutic strategies for cardiovascular disease management and prevention.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.